9/2/2010

Pfizer agreed to purchase FoldRx Pharmaceuticals, a biotech firm that is developing a drug to treat a rare neurodegenerative disease, for an undisclosed amount. The acquisition, expected to conclude this year, is in line with Pfizer's strategy of increasing its portfolio of medicines for rare disorders.

Related Summaries